Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. is a life sciences company focused on proteomics technology that completed a de-SPAC merger with Endeavour Acquisition Corp (Nasdaq: ENDL), a blank-check vehicle sponsored by Endeavour Holdings LLC that conducted its IPO in 2020. The combined company began trading on Nasdaq under the ticker NAUT following the deal's close in June 2021. The 10-Q filing dated May 13, 2021, accession number 0001140361-21-017275, represents a quarterly disclosure submitted ahead of that merger close, reflecting Nautilus's status as an emerging-growth registrant operating in the life sciences and proteomics sector. Sign up for SpacDesk to access the full filing history, timeline data, and sponsor profiles for Nautilus Biotechnology and hundreds of other SPAC transactions.